Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Catalyst Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX XLO
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.